INS and breast cancer: The majority of the patients who took metformin as monotherapy (67.3%) did not suffer from breast cancer, and only 0.78%, i.e., 28.9% of all the patients, were diagnosed with breast cancer; this was followed by patients taking metformin and insulin, with 14.4% not suffering from breast cancer; however, the total parentage of patients using other medication with metformin had a higher percentage of breast cancer (1.92%, i.e., 71.1%) (Figure 5).